Publicaciones en las que colabora con David Jiménez Castro (48)

2024

  1. Clinical outcomes after discontinuing anticoagulant therapy in patients with first unprovoked venous thromboembolism

    Journal of Thrombosis and Haemostasis, Vol. 22, Núm. 8, pp. 2234-2246

  2. The prognostic value of blood cellular indices in pulmonary embolism

    American Journal of Hematology, Vol. 99, Núm. 9, pp. 1704-1711

2023

  1. A second update on mapping the human genetic architecture of COVID-19

    Nature

  2. Erratum to: Mapping the human genetic architecture of COVID-19 (Nature, (2021), 600, 7889, (472-477), 10.1038/s41586-021-03767-x)

    Nature

  3. Feasibility of a screening algorithm for chronic thromboembolic pulmonary hypertension: The OSIRIS study

    Thrombosis Research, Vol. 228, pp. 1-9

2022

  1. Detailed stratified GWAS analysis for severe COVID-19 in four European populations

    Human Molecular Genetics, Vol. 31, Núm. 23, pp. 3945-3966

  2. Randomised controlled trial of a prognostic assessment and management pathway to reduce the length of hospital stay in normotensive patients with acute pulmonary embolism

    The European respiratory journal, Vol. 59, Núm. 2

2021

  1. Association between preexisting versus newly identified atrial fibrillation and outcomes of patients with acute pulmonary embolism

    Journal of the American Heart Association, Vol. 10, Núm. 17

  2. Clinical characteristics and 3-month outcomes in cancer patients with incidental versus clinically suspected and confirmed pulmonary embolism

    European Respiratory Journal, Vol. 58, Núm. 1

  3. Comparative clinical prognosis of massive and non-massive pulmonary embolism: A registry-based cohort study

    Journal of Thrombosis and Haemostasis, Vol. 19, Núm. 2, pp. 408-416

  4. Effect of a Pulmonary Embolism Diagnostic Strategy on Clinical Outcomes in Patients Hospitalized for COPD Exacerbation: A Randomized Clinical Trial

    JAMA - Journal of the American Medical Association, Vol. 326, Núm. 13, pp. 1277-1285

  5. Mapping the human genetic architecture of COVID-19

    Nature, Vol. 600, Núm. 7889, pp. 472-477

  6. Symptomatic subsegmental versus more central pulmonary embolism: Clinical outcomes during anticoagulation

    Research and Practice in Thrombosis and Haemostasis, Vol. 5, Núm. 1, pp. 168-178

  7. Timing and characteristics of venous thromboembolism after noncancer surgery

    Journal of Vascular Surgery: Venous and Lymphatic Disorders, Vol. 9, Núm. 4, pp. 859-867.e2

2020

  1. Correction to: Vena cava filters in patients presenting with major bleeding during anticoagulation for venous thromboembolism (Internal and Emergency Medicine, (2019), 14, 7, (1101-1112), 10.1007/s11739-019-02077-5)

    Internal and Emergency Medicine

  2. D-dimer levels and risk of recurrence following provoked venous thromboembolism: findings from the RIETE registry

    Journal of Internal Medicine, Vol. 287, Núm. 1, pp. 32-41

  3. Derivation and validation of a clinical prediction rule for thrombolysis-associated major bleeding in patients with acute pulmonary embolism: The BACS score

    European Respiratory Journal, Vol. 56, Núm. 6

  4. First three months of anticoagulation for venous thromboembolism in non-cancer patients: LMWH VS. VKAs. Findings from the RIETE registry

    Thrombosis Update, Vol. 1

  5. Genomewide association study of severe covid-19 with respiratory failure

    New England Journal of Medicine, Vol. 383, Núm. 16, pp. 1522-1534

  6. Incidence of major adverse cardiovascular events among patients with provoked and unprovoked venous thromboembolism: Findings from the Registro Informatizado de Enfermedad Tromboembólica Registry

    Journal of Vascular Surgery: Venous and Lymphatic Disorders, Vol. 8, Núm. 3, pp. 353-359.e1